Press Release


Poxel Reports Financial Results for Full Year 2024
and Provides Operational and Financial Update

• First positive net royalties1, driven by TWYMEEG® royalties and a one-time
sales-based payment of JPY 500 million, fully allocated to OrbiMed
• Change in governance effective since August 1st, 2025, following the filing of
a declaration of insolvency (déclaration de cessation des paiements) and a
request to open reorganization proceedings (redressement judiciaire) with
the Court for Economic Activities of Lyon
• Opening of reorganization proceedings decided at the hearing held on
August 5, 2025, with a six-month observation period running until February
5, 2026:
o Interim hearing on October 2, 2025, confirming the continuation of the
observation period to allow for the preparation of a continuation plan
o Depending on its final terms, the continuation plan to be established
will be submitted to shareholders for approval in due course
• The Statutory Auditors have stated that they are unable to certify Poxel’s
2024 financial statements, given the material uncertainty regarding the
Company’s ability to continue as a going concern arising from the
aforementioned judicial reorganization proceedings
• Continued commercial momentum for TWYMEEG® in Japan: +26% growth in
sales in the second quarter of 2025 (April-June) compared to the previous
quarter (January-March)
• Cash position of EUR 1.2 million as of September 30, 2025, including the
drawdown of a first tranche of EUR 500 thousand on the bond issue for a
maximum amount of EUR 2.5 million made available by IPF Partners,
providing the Company with financial visibility through the end of the
observation period


Webinar in French today at 6:00 p.m. (Paris time):
To register for the webinar: click on this link.
A presentation will be available on Poxel's website in the Investors section.

1
Under the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of
TWYMEEG®, independent of the level of sales. All royalties that Poxel receives from TWYMEEG ® net sales above that 8%
level are considered as positive net royalties. Net royalties will therefore be positive for Poxel when TWYMEEG ® net sales
exceed JPY 5 billion in a fiscal year and royalties reach 10% and above.




1
LYON, France, October 16, 2025 – POXEL SA (Euronext : POXEL - FR0012432516),
a clinical stage biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including metabolic
dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders,
today announces its financial results for the year ended December 31, 2024, and
provides an update on its operational and financial position.

Nicolas Trouche, Chief Executive Officer of Poxel, stated: “Having taken over the
management of the Company a few weeks ago, Poxel's new leadership team has
made ensuring the Company's long-term viability its top priority. We are also focused
on maximizing the value of our assets, the quality of which is reflected in TWYMEEG®’s
continued positive trajectory in Japan, with further sales growth in the second quarter
of 2025. To this end, we are working on a continuation plan while maintaining a
constructive dialogue with the court-appointed representatives and our creditors. We
will continue to keep the market informed as key milestones are reached.”

Full-Year 2024 Income Statement (IFRS Standards)

EUR (in thousands) FY FY
2024 2023
12 months 12 months
Revenue 6,636 1,981
Cost of sales (2,943) (1,980)
Gross margin 3,693 1
Net research and development
(840) (3,823)
expenses*
Impairment of
- (16,572)
intangible assets (PXL065)
General and administrative
(6,354) (8,370)
expenses
Operating income (loss) (3,501) (28,764)
Financial income (expenses) (14,802) (6,325)
Income tax (2) (2)
Net income (loss) (18,305) (35,090)
*Net of R&D tax credit


As announced in the press release dated February 19, 2025 2 , Poxel reported
consolidated revenue of EUR 6.6 million for the year ended December 31, 2024, as
compared to EUR 2.0 million during the corresponding period in 2023.




2
"Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook”




2
Consolidated revenue for 2024 mostly reflects the JPY 580 million (EUR 3.6 million3)
of royalty revenue from Sumitomo Pharma, which represents:
- 8% of TWYMEEG® net sales in Japan for 2024 Q1 to Q3,
- 10% of TWYMEEG® net sales in Japan for 2024 Q4 and a 2% catch up of the
net sales related to 2024 Q2 and Q3 following the achievement of the JPY 5
billion net sales threshold for Sumitomo Pharma’s 2024 fiscal year started on
April 1st, 2024.
As part of the Merck Serono licensing agreement, Poxel pays Merck Serono a fixed
8% royalty based on the net sales of Imeglimin, independent of the level of sales.
Consolidated revenue for 2024 Q4 also includes the sales based payment of JPY
500 million (EUR 3.1 million3). In accordance with the Royalty Monetization
agreement with OrbiMed, all positive net royalties and milestone payments are
fully allocated to the repayment of the debt.

Cost of sales amounted to EUR 2.9 million, corresponding to the 8% royalties on
net sales of Imeglimin in Japan due to Merck Serono, as part of the Merck Serono
license agreement.

R&D expenses totaled EUR 0.8 million in 2024, as compared to EUR 3.8 million in
2023, mainly related to Intellectual Property costs, wages and social charges.
Those are net of the R&D Tax Credit (CIR) that represented income of EUR 0.2
million in 2024, as compared to EUR 0.6 million in 2023.

General and administrative expenses totaled EUR 6.4 million in 2024, as compared
to EUR 8.4 million in 2023, mainly related to fees associated with the monetization
transaction with OrbiMed, the restructuring of the Company's debt, and personnel
expenses.

The financial loss amounted to EUR 14.8 million in 2024, as compared to a loss of
EUR 6.3 million in 2023, primarily reflecting interest expense on the Company’s
indebtedness and early repayment of the IPF Partners debt.
In total, net loss for the financial period ending December 31, 2024, was EUR 18.3
million, significantly reduced as compared to a net loss of EUR 35.1 million in 2023,
which was impacted by the EUR 16.6 million impairment of PXL065.


Consolidated cash and cash equivalents (unaudited data)
As a reminder, as of December 31, 2024, total consolidated cash and cash
equivalents were EUR 3.7 million. As of September 30, 2025, cash and cash
equivalents amounted to EUR 1.2 million. This amount includes the drawdown of a
first tranche of EUR 500 thousand under the bond financing facility of up to EUR
2.5 million made available by IPF Partners.

3
Converted at the exchange rate on December 31, 2024




3
EUR (in thousands) Q3 2025 Q4 2024

Cash 1,157(1) 3,657(2)
Cash equivalents - -
Total cash and cash equivalents 1,157 3,657

(1) Including EUR 563 thousand corresponding to cash held in escrow accounts to secure their financing over several
years, in accordance with the royalty monetization agreement

(2) Excluding OrbiMed deposit of EUR 4.8 million (USD 5 million) that was allocated in Q1 2025 to the reimbursement of the
IPF Partners debt as per bonds documentation




Update on financing
Poxel and IPF Partners have agreed on the provision of a bond loan of up to EUR
2.5 million to finance the Company’s general needs and/or its working capital
requirements as part of the judicial reorganization proceedings initiated on August
5, 2025.
This new financing, structured as an additional Tranche D under the IPF bond loan,
consists, for the time being, of the use of plain vanilla bonds rather than bonds with
warrants. It should be noted that these warrants bear capitalized interest of 27%
and are subject to the same repayment terms as those of Tranche C, namely
repayment based on Poxel’s positive net TWYMEEG® royalties, following the full
repayment of OrbiMed’s claim4.
This loan follows the announcement made by the Company as part of the
operational and financial transition plan initiated by Poxel, with the support of IPF
Partners, as detailed in its press release dated July 29, 2025.
The Company has thus drawn down an initial EUR 500 thousand under this
financing facility.
Further drawdowns will be made on an as-needed basis, up to a total amount of
EUR 2.5 million. The total drawdowns should enable the Company to extend its
cash runway through the end of the observation period, excluding any potential
renewal, i.e. February 5, 2026.




4
Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million




4
Significant post-closing events
Governance
At its meeting on July 31, 2025, the Company's Board of Directors co-opted four
new directors, who took office immediately:
• Ms. Sophie Jacq Lapointe;
• Mr. Nicolas Trouche;
• Mr. Amit Kohli; and
• Mr. Alexandre Bragadir.
These co-optations will be submitted for ratification at the Company's next Annual
General Meeting of Shareholders.
Sophie Jacq Lapointe was elected Chairman of the Company’s Board and Nicolas
Trouche was appointed Chief Executive Officer of the Company.


Update on the reorganization proceedings
Following the filing of a declaration of insolvency, the Court for Economic Activities
of Lyon opened judicial reorganization proceedings on August 5, 2025, marking the
beginning of a six-month observation period running until February 5, 2026. During
this period, the Company continues its operations and is working on the
preparation of a continuation plan in consultation with the court-appointed
administrator and its creditor, IPF Partners. This plan will be disclosed to the market
once it has been approved by the Board of Directors. Depending on its
characteristics, the continuation plan, once finalized, will be submitted to
shareholders for approval in due course.


Availability of the 2024 Universal Registration Document and going concern risk
The Company will make its 2024 Universal Registration Document available to the
public and file it with the Autorité des marchés financiers (AMF) no later than
October 31, 2025. The document will include the Statutory Auditors’ reports relating
to the audit of the financial statements for the year ended December 31, 2024.
In preparing the financial statements for the year ended December 31, 2024, the
Board of Directors adopted the going concern assumption.
Significant uncertainties remain regarding Poxel’s situation, in particular the
outcome of the ongoing continuation plan and the Company’s limited cash runway
through the end of the observation period. These factors represent a material risk
to Poxel’s ability to continue as a going concern. As a result, the Statutory Auditors
have indicated that their reports will state that it was not possible to certify the
financial statements as of December 31, 2024 (both consolidated and statutory),




5
due to their inability to assess the appropriateness of the going concern
assumption applied.
In parallel, the Company announces that its next Annual General Meeting will be
convened on December 11, 2025. At this meeting, shareholders will be asked to
approve the 2024 annual and consolidated financial statements and to present the
continuation plan.


Commercial Review in the second quarter of 2025
Update on TWYMEEG® (Imeglimin)
• For the quarter ended June 2025, TWYMEEG® gross sales in Japan totalled JPY
2.4 billion (EUR 23.0 million5) compared to JPY 1.9 billion (EUR 10.9 million5) in
the previous quarter, as reported by Sumitomo Pharma.

• For its FY 20256, Sumitomo Pharma forecasts gross sales for TWYMEEG® of JPY
11.2 billion (EUR 64.4 million5) which would represent a 47% increase over FY
2024. This forecast includes an incremental uptake among type 2 diabetic
patients with renal impairment following the recent approval by the
Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to revise
TWYMEEG® package insert for patients with renal impairment with eGFR
(estimated glomerular filtration rate) less than 45 mL/min/1.73m2.

• Based on this FY 2025 forecast, TWYMEEG® could reach JPY 10 billion net sales
(EUR 57.5 million5) entitling Poxel to receive 12% royalties on all TWYMEEG® net
sales and a second sales-based payment of JPY 1 billion (EUR 5.8 million5). In
accordance with the royalty monetization agreement entered into with
OrbiMed, these proceeds will be exclusively allocated to the reimbursement of
the bonds issuance. Beyond 2025, Poxel expects to receive escalating double-
digit royalties as well as additional sales-based payments upon achievement of
contractually based sales thresholds.

Second Quarter and First Half 2025 Revenue (unaudited data)

Poxel reported revenue of EUR 2,090 thousand for the six months ended June 30,
2025, as compared to EUR 1,162 thousand revenue during the corresponding
period in 2024, up +80%.

Revenue for the first half of 2025 reflects JPY 345 million (EUR 2,090 thousand5) of
royalty revenue from Sumitomo Pharma which represents 10% of TWYMEEG® net
sales in Japan for the first quarter and 8% for the second quarter. Based on the

5
Converted at the exchange rate as of September 30, 2025
6
Sumitomo Pharma fiscal year 2025 ends March 31, 2026




6
current forecast, Poxel expects to receive at least 12% royalties on TWYMEEG® net
sales in Japan from Sumitomo Pharma. As part of the Merck Serono licensing
agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales
of Imeglimin, independent of the level of sales. In accordance with the royalty
monetization agreement entered into with OrbiMed, net positive royalties will be
allocated in full to the repayment of the bonds.


EUR (in thousands) Q1 2025 Q2 2025 H1 2025 Q1 2024 Q2 2024 H1 2024
3 months 3 months 6 months 3 months 3 months 6 months
Sumitomo Pharma
Agreement
1,0667 1,0248 2,090 449 713 1,162
Other - - - - - -
Total revenues 1,066 1,024 2,090 449 713 1,162
Unaudited data


A first document summarizing the main topics raised by shareholders over the
past few months, notably regarding:
• the strategy of past partnership agreements,
• current relations with Merck Serono,
• the commercial partnership with Sumitomo Pharma for TWYMEEG® in
Japan, and
• the rights related to Roivant,
will be made available over the next days on the Company’s website, in the
“Investors” section, under “Shareholder Information”, “Documentation”.


About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative
treatments for chronic serious diseases with metabolic pathophysiology,
including metabolic dysfunction-associated steatohepatitis (MASH) and rare
disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R-
pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In
rare diseases, development of PXL770, a first-in-class direct adenosine
monophosphate-activated protein kinase (AMPK) activator, is focused on the
treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic
kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel’s first-in-class product that
targets mitochondrial dysfunction, is now marketed for the treatment of type 2
diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and
sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma

7
Converted at the exchange rate as of March 31, 2025
8
Converted at the exchange rate as of June 30, 2025




7
for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon,
France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release
about future events are subject to (i) change without notice and (ii) factors beyond
the Company’s control. These statements may include, without limitation, any
statements preceded by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can
have,” “likely,” “should,” “would,” “could” and other words and terms of similar
meaning or the negative thereof. Forward-looking statements are subject to
inherent risks and uncertainties beyond the Company’s control that could cause
the Company’s actual results or performance to be materially different from the
expected results or performance expressed or implied by such forward-looking
statements. The Company does not endorse or is not otherwise responsible for the
content of external hyperlinks referred to in this press release.

Contacts - Investor relations / Media

NewCap
Aurélie Manavarere, Théo Martin / Arthur Rouillé
investors@poxelpharma.com
+33 1 44 71 94 94




8